Home / Deep Research / Cockayne Syndrome

Cockayne Syndrome

Cockayne Syndrome (CS): Disease Characteristics Research Report

2026-04-25
Falcon MONDO:0016006 Model: Edison Scientific Literature 57 citations

Cockayne Syndrome (CS): Disease Characteristics Research Report

Target Disease

1. Disease Information

1.1 Concise overview (current understanding)

Cockayne syndrome (CS) is a rare, autosomal-recessive multisystem disorder characterized by microcephaly, impaired postnatal growth, and premature pathological aging, with additional frequent manifestations including hearing loss, cataracts, retinal dystrophy, developmental delay, and photosensitivity. (wilson2016thecockaynesyndrome pages 1-2, vessoni2020cockaynesyndromethe pages 1-2)

Quote (abstract-level; primary natural history study): “Cockayne syndrome (CS) is a rare, autosomal-recessive disorder characterized by microcephaly, impaired postnatal growth, and premature pathological aging.” (wilson2016thecockaynesyndrome pages 1-2)

CS is strongly linked to defective transcription-coupled nucleotide excision repair (TC-NER) and/or transcription-associated genome maintenance, and is widely considered both a neurodevelopmental and neurodegenerative condition. (vessoni2020cockaynesyndromethe pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3)

1.2 Key identifiers

Direct identifier evidence for core CS was not present in the retrieved excerpts (e.g., OMIM, Orphanet/ORPHA, MeSH, ICD-10/11, MONDO). This report therefore flags these identifiers as not captured from the retrieved corpus.

However, for the XP–CS complex (Xeroderma pigmentosum–Cockayne syndrome overlap), the following were explicitly provided: - Orphanet (ORPHA): 220295 (XP-CS) (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2) - OMIM: 278730, 278760, 278780, 610651 (XP-CS) (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)

1.3 Synonyms and alternative names

1.4 Evidence source type

The disease characterization here is derived from: - Aggregated disease-level resources (large natural history cohort) (wilson2016thecockaynesyndrome pages 2-3) - Clinically confirmed cohorts and scoring-system validations (spitz2021diagnosticandseverity pages 1-2) - Imaging cohorts (koob2010neuroimagingincockayne pages 1-2) - Recent mechanistic/model-system studies (patient-derived fibroblasts; iPSC organoids) (chikhaoui2024supplementationwithnicotinamide pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3) - Clinical trial registry records (NCT01142154 chunk 1, NCT03044210 chunk 1, NCT00001813 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants affecting transcription-coupled repair and transcription-associated genome maintenance. - Core causal genes: ERCC6 (CSB) and ERCC8 (CSA) (vessoni2020cockaynesyndromethe pages 1-2, wilson2016thecockaynesyndrome pages 2-3) - Functional hallmark: patient fibroblasts show marked UV sensitivity with defective recovery of RNA synthesis after UV irradiation—consistent with impaired TC-NER (vessoni2020cockaynesyndromethe pages 1-2)

2.2 Risk factors

2.3 Protective factors

No validated protective genetic variants or environmental protective factors were identified in the retrieved evidence corpus.

2.4 Gene–environment interactions

The retrieved evidence emphasizes UV-induced transcription-blocking lesions as a mechanistic trigger in cellular assays (UV sensitivity; recovery of RNA synthesis), but it does not provide formal human gene–environment interaction analyses. (vessoni2020cockaynesyndromethe pages 1-2)

3. Phenotypes (clinical spectrum)

3.1 Core phenotypes and frequencies (CoSyNH natural history cohort)

In the CoSyNH cohort (n=102), all participants were microcephalic with severe postnatal growth failure (wilson2016thecockaynesyndrome pages 2-3). Reported phenotype frequencies include: - Muscle weakness: 80/102 (~78%) (wilson2016thecockaynesyndrome pages 2-3) - Hearing loss: 64/102 (~63%); in a subset analysis, 44% had conductive/mixed hearing loss and onset/progression were common through childhood (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 2-3) - Tremor: 66/102 (~65%) (wilson2016thecockaynesyndrome pages 2-3) - Joint contractures: 64/102 (~63%) (wilson2016thecockaynesyndrome pages 2-3) - Gastroesophageal reflux: 54/102 (~53%) (wilson2016thecockaynesyndrome pages 2-3) - Scoliosis: 49/102 (~48%) (wilson2016thecockaynesyndrome pages 2-3) - Cataracts: 47/102 (~46%) (wilson2016thecockaynesyndrome pages 2-3) - Seizures: 23/102 (~23%) (wilson2016thecockaynesyndrome pages 6-8, wilson2016thecockaynesyndrome pages 2-3) - Respiratory disease: 20/102 (~20%) (wilson2016thecockaynesyndrome pages 2-3)

Additional clinical/laboratory abnormalities: - Subcutaneous fat loss: 56% (wilson2016thecockaynesyndrome pages 6-8) - Deranged liver function tests: 63% among those tested (n=71) (wilson2016thecockaynesyndrome pages 6-8) - Brain imaging abnormalities: 83.5% (71/85 imaged) (wilson2016thecockaynesyndrome pages 6-8) - Intracranial calcification: 55% (47/85) (wilson2016thecockaynesyndrome pages 6-8) - White matter changes: 38% (33/85) (wilson2016thecockaynesyndrome pages 6-8)

3.2 Adult/late-stage neurologic phenotype (2024 development)

A 2024 multicenter retrospective cohort of adults with CS who survived beyond age 18 (n=18) reported high late-stage neurologic burden: - Neurocognitive/neuropsychiatric decline: 17/18 (94.4%) (rajamani2024cognitivedeclineand pages 5-9) - Tremor: 15/18 (83.3%); peripheral neuropathy: 13/18 (72.2%) (rajamani2024cognitivedeclineand pages 5-9) - Progressive language decline: 15/17 (88.2%) (rajamani2024cognitivedeclineand pages 5-9) - Seizures: 5/18 (27.8%); stroke/TIA: 4/18 (22.2%) (rajamani2024cognitivedeclineand pages 5-9) - Neuroimaging among those with imaging: diffuse brain atrophy 13/15 (86.7%), white matter changes 12/15 (80.0%), basal ganglia calcifications 11/15 (73.3%) (rajamani2024cognitivedeclineand pages 5-9)

3.3 Phenotype ontology mapping (HPO suggestions; non-exhaustive)

(These are suggested HPO labels for knowledge-base normalization; the retrieved excerpts did not provide HPO IDs.) - Microcephaly; progressive postnatal microcephaly (wilson2016thecockaynesyndrome pages 2-3) - Postnatal growth retardation / failure to thrive (wilson2016thecockaynesyndrome pages 2-3) - Photosensitivity (cutaneous) (wilson2016thecockaynesyndrome pages 3-4) - Cataract (early-onset; bilateral common) (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 9-10) - Sensorineural hearing impairment / hearing loss (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 2-3) - Retinal dystrophy / retinal atrophy (wilson2016thecockaynesyndrome pages 1-2) - Tremor (wilson2016thecockaynesyndrome pages 6-8) - Spasticity; areflexia (used in diagnostic scoring) (spitz2021diagnosticandseverity pages 1-2) - Joint contractures; Achilles tendon contracture (wilson2016thecockaynesyndrome pages 3-4, chen2025clinicalandgenetic pages 1-2) - Gastroesophageal reflux (wilson2016thecockaynesyndrome pages 3-4) - Seizures (wilson2016thecockaynesyndrome pages 6-8) - Leukodystrophy / white matter abnormalities; hypomyelination (koob2010neuroimagingincockayne pages 1-2) - Intracranial calcifications (basal ganglia/putamen) (koob2010neuroimagingincockayne pages 1-2) - Peripheral neuropathy (rajamani2024cognitivedeclineand pages 5-9)

3.4 Quality-of-life impact

The retrieved corpus did not include disease-specific EQ-5D/SF-36/PROMIS statistics. However, the high prevalence of feeding difficulties/GERD, progressive neurologic decline, sensory impairment, and contractures strongly implies major limitations in mobility, communication, and daily activities, especially in later stages. (wilson2016thecockaynesyndrome pages 3-4, rajamani2024cognitivedeclineand pages 5-9)

4. Genetic / Molecular Information

4.1 Causal genes and inheritance

4.2 Pathogenic variant types (examples from retrieved evidence)

Population allele frequencies (gnomAD), detailed ClinVar classifications, and comprehensive variant spectra were not retrievable from the current evidence corpus.

4.3 Modifier genes / epigenetics

No modifier genes or epigenetic biomarkers were explicitly identified in the retrieved evidence.

5. Environmental Information

CS is a genetic disorder. The retrieved evidence highlights UV sensitivity and UV-induced transcription-blocking lesions as a mechanistic trigger in cellular assays rather than an epidemiologic environmental risk factor for disease onset. (vessoni2020cockaynesyndromethe pages 1-2)

6. Mechanism / Pathophysiology

6.1 Canonical mechanism: transcription-coupled repair and transcription stress

Patient fibroblasts exhibit UV hypersensitivity with defective recovery of RNA synthesis after UV irradiation, reflecting impaired TC-NER/transcription-associated repair of transcribed genes. (vessoni2020cockaynesyndromethe pages 1-2)

A mechanistic cascade consistent with retrieved evidence: 1) Transcription-blocking DNA lesions (e.g., UV-induced) stall transcription complexes; 2) defective CSA/CSB-dependent transcription-coupled repair leads to persistent transcription stress; 3) downstream consequences include impaired neurodevelopmental programs and progressive neurodegeneration. (vessoni2020cockaynesyndromethe pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3)

6.2 2024 mechanistic development: neurodevelopmental transcriptomics in iPSC-derived organoids

In CSB-deficient patient-derived neurospheres and cerebral organoids, RNA-seq showed: - Neurospheres: upregulation of VEGFA-VEGFR2 signaling, vesicle-mediated transport, and head-development programs (szepanowski2024cockaynesyndromepatient pages 1-3) - Organoids: downregulation of brain development, neuron projection development, and synaptic signaling (szepanowski2024cockaynesyndromepatient pages 1-3) - Shared metabolic signature: upregulated steroid biosynthesis—specifically the cholesterol biosynthesis branch (szepanowski2024cockaynesyndromepatient pages 1-3, szepanowski2024cockaynesyndromepatient pages 19-21)

These findings support CS as both neurodevelopmental and neurodegenerative. (szepanowski2024cockaynesyndromepatient pages 1-3)

6.3 2024 mechanistic development: oxidative stress, NRF2 repression, and NAD biology (nicotinamide study)

In patient-derived fibroblasts, oxidative-stress profiling identified two major altered pathways: activation of arachidonic acid metabolism and repression of the NRF2 pathway. Nicotinamide (NAM) supplementation was reported to “adjust[] these abnormalities by enhancing autophagy and decreasing inflammation,” and to restore CSA/CSB-dependent depletion of POLG1 in fibroblasts. (chikhaoui2024supplementationwithnicotinamide pages 1-2)

Interpretation (expert analysis): these data suggest that impaired genome maintenance in CS may propagate a chronic stress phenotype involving redox imbalance, inflammation, and mitochondrial maintenance defects, which may be partially modifiable in vitro through NAD precursor supplementation; however, the evidence remains exploratory and cell-based. (chikhaoui2024supplementationwithnicotinamide pages 1-2, chikhaoui2024supplementationwithnicotinamide pages 9-11)

6.4 Ontology suggestions

7. Anatomical Structures Affected

7.1 Organ and system level (human evidence)

7.2 UBERON / GO cellular component suggestions

8. Temporal Development (onset and progression)

8.1 Typical onset

CS spans a wide severity spectrum “ranging from severe prenatal onset to mild adult-onset subtypes.” (spitz2021diagnosticandseverity pages 1-2)

8.2 Progression

Progressive neurologic impairment is typical; late-stage adult survivors commonly develop neurocognitive/neuropsychiatric decline, tremor, neuropathy, and sometimes seizures/stroke. (rajamani2024cognitivedeclineand pages 5-9)

9. Inheritance and Population

9.1 Epidemiology (recently used/commonly cited values in retrieved evidence)

9.2 Prognosis statistics (natural history and prognostic factors)

In CoSyNH (n=102): mean age 11.5 years; 28/102 deceased at analysis with mean age at death 8.4 years (range 17 months–30 years). (wilson2016thecockaynesyndrome pages 2-3)

A key prognostic factor is early cataracts: - Cataracts before age 3 were strongly associated with younger age at death; 5-year survival ~60% with early cataracts vs ~95% without. (wilson2016thecockaynesyndrome pages 9-10)

10. Diagnostics

10.1 Clinical and radiologic patterning

Characteristic imaging patterns include hypomyelination, putaminal/basal ganglia calcifications, and progressive cerebral/cerebellar atrophy; MR spectroscopy often shows elevated lactate and decreased NAA/Cho. This pattern helps differentiate CS from other childhood leukoencephalopathies or calcification syndromes. (koob2010neuroimagingincockayne pages 1-2, koob2010neuroimagingincockayne pages 7-8)

10.2 Validated diagnostic/severity scoring (Orphanet J Rare Dis, 2021)

Spitz et al. developed: - A 10-item clinical diagnostic score (short stature; enophthalmos; hearing loss; cataracts; cutaneous photosensitivity; frequent dental caries; enamel hypoplasia; abnormal tooth morphology; areflexia; spasticity) with 95.7% sensitivity and 86.4% specificity at threshold 8.5. (spitz2021diagnosticandseverity pages 1-2, spitz2021diagnosticandseverity pages 4-5) - A 12-item clinical-radiologic score (adds leukodystrophy and brain calcifications) with 96.2% sensitivity and 96.8% specificity at threshold 15.5. (spitz2021diagnosticandseverity pages 4-5) - A 5-domain severity score (head circumference; growth failure; neurosensorial signs; motor autonomy; communication) for longitudinal tracking. (spitz2021diagnosticandseverity pages 1-2)

10.3 Molecular testing strategy

The CoSyNH group recommends first-line molecular testing of CSA/CSB using DNA obtained from blood/mouthwash/dried bloodspots, minimizing the need for skin biopsy, and notes there is no cure so diagnosis supports prognostic counseling and care coordination. (wilson2016thecockaynesyndrome pages 9-10)

10.4 Functional assays

A key functional hallmark is defective recovery of RNA synthesis after UV irradiation in patient fibroblasts (recovery RNA synthesis-type assays), reflecting TC-NER dysfunction. (vessoni2020cockaynesyndromethe pages 1-2)

10.5 Differential diagnosis (imaging-guided examples)

Koob et al. emphasize that the combined imaging features help distinguish CS from congenital CMV, Aicardi–Goutières syndrome, Pelizaeus–Merzbacher disease, and some mitochondrial disorders. (koob2010neuroimagingincockayne pages 7-8, koob2010neuroimagingincockayne pages 8-9)

11. Outcome / Prognosis

11.1 Survival and life expectancy

Severity-group summaries in reviews commonly cite approximate life expectancy of ~5 years (severe), ~16 years (classical), and >30 years (mild). (vessoni2020cockaynesyndromethe pages 1-2)

Real-world cohort outcome data from CoSyNH: mean age at death 8.4 years (range 17 months–30 years) in the cross-sectional analysis, and early cataracts are a strong negative prognostic indicator. (wilson2016thecockaynesyndrome pages 2-3, wilson2016thecockaynesyndrome pages 9-10)

11.2 Causes of death

Quote (review): “In all cases, pneumonia/respiratory ailments are the most common causes of death.” (vessoni2020cockaynesyndromethe pages 1-2)

12. Treatment

12.1 Current applications and real-world implementation (supportive care)

There is no curative therapy; care emphasizes surveillance and complication management. (wilson2016thecockaynesyndrome pages 9-10)

Key care recommendations from CoSyNH include: - Multidisciplinary follow-up, including hearing/vision surveillance and feeding management (wilson2016thecockaynesyndrome pages 3-4) - Feeding support with careful titration of NG/PEG feeding to avoid rapid weight gain and complications (wilson2016thecockaynesyndrome pages 3-4) - Medication safety: avoid metronidazole due to reports of fatal acute hepatic failure; exercise added caution with opioids/sedatives (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 8-9)

MAXO suggestions (examples): supportive care; nutritional support/enteral feeding; physical therapy; hearing evaluation; cataract monitoring; genetic testing; genetic counseling (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 9-10).

12.2 Experimental / translational developments (2024)

12.3 Clinical trials (registry evidence)

  • Prodarsan™ (D-mannitol) PK/safety trial: NCT01142154; Phase I/II open-label, single group; n=5; primary endpoint was D-mannitol pharmacokinetics comparing IV Osmitrol vs oral Prodarsan; completed (start 2010-06; completion 2011-02). URL: https://clinicaltrials.gov/study/NCT01142154 (NCT01142154 chunk 1)
  • Metabolic study (indirect calorimetry): NCT03044210; interventional basic-science metabolic evaluation; planned n=25; terminated for insufficient participants; listed completion 2024-08-01. URL: https://clinicaltrials.gov/study/NCT03044210 (NCT03044210 chunk 1)
  • NIH DNA repair disorders protocol: NCT00001813; observational prospective protocol including CS, XP, TTD; enrollment 709; completed; updated 2026-04-22. URL: https://clinicaltrials.gov/study/NCT00001813 (NCT00001813 chunk 1)
  • DNage natural history study: NCT00985413; observational pediatric natural history focusing on growth and hearing; terminated due to sponsor receivership. (NCT00985413 chunk 1)

13. Prevention

Primary prevention for CS is genetic (reproductive) rather than environmental. - Genetic counseling is indicated due to autosomal recessive inheritance and recurrence risk. (wilson2016thecockaynesyndrome pages 1-2) - Preimplantation genetic testing (PGT-M): implemented for an ERCC6-variant family with a successful pregnancy reported (proof-of-feasibility for prevention of transmission in affected families). (nascimento2022neurodegeneraçãonoenvelhecimento pages 46-66)

No proven lifestyle/environmental preventive measures were identified in the retrieved evidence.

14. Other Species / Natural Disease

No naturally occurring Cockayne-syndrome analog in non-human species was identified in the retrieved evidence. (Model-system evidence was primarily human cells and literature references.)

15. Model Organisms / Model Systems

15.1 Patient-derived cellular models (real-world research implementations)

15.2 iPSC and organoid models (2024)

Structured summary artifact

Table (click to expand)
Topic Key points (include numbers where available) Evidence type Key sources (include DOI/URL and publication date) Citation IDs
Disease definition and genes Ultra-rare autosomal recessive multisystem/neurodevelopmental-progeroid disorder with defective transcription-coupled nucleotide excision repair (TC-NER). Main causal genes: ERCC6/CSB and ERCC8/CSA. ERCC6 accounts for ~70–75% of molecularly solved cases in several summaries/cohorts. Human clinical cohort; review Vessoni et al., Genet Mol Biol (2020-05), DOI: 10.1590/1678-4685-gmb-2019-0085, https://doi.org/10.1590/1678-4685-gmb-2019-0085; Wilson et al., Genet Med (2016-05), DOI: 10.1038/gim.2015.110, https://doi.org/10.1038/gim.2015.110; He et al., Front Genet (2024-10), DOI: 10.3389/fgene.2024.1435622, https://doi.org/10.3389/fgene.2024.1435622 (vessoni2020cockaynesyndromethe pages 1-2, wilson2016thecockaynesyndrome pages 2-3, nascimento2022neurodegeneraçãonoenvelhecimento pages 46-66)
XP-CS overlap genes Xeroderma pigmentosum–Cockayne syndrome complex (XP-CS) combines CS neurodegeneration/developmental disease with XP photosensitivity/cancer susceptibility. Reported XP-CS genes: ERCC3/XPB, ERCC2/XPD, ERCC4/XPF, ERCC5/XPG; in a literature series of 43 XP-CS patients, 42 were molecular/biochemical confirmed, with most in XP-G then XP-D groups. Literature review of human cases Natale & Raquer, Orphanet J Rare Dis (2017-04), DOI: 10.1186/s13023-017-0616-2, https://doi.org/10.1186/s13023-017-0616-2 (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)
Epidemiology Estimated prevalence/incidence figures vary by source: ~2.7 per million births in Western Europe/Japan; 1/360,000 births in Western Europe; some recent clinical reports cite ~1 in 250,000 live births and prevalence 2.5 per million. Review; diagnostic-score cohort; case series Vessoni et al. (2020-05) https://doi.org/10.1590/1678-4685-gmb-2019-0085; Spitz et al., Orphanet J Rare Dis (2021-02), DOI: 10.1186/s13023-021-01686-8, https://doi.org/10.1186/s13023-021-01686-8; Chen et al., Front Genet (2025-08), DOI: 10.3389/fgene.2025.1591551, https://doi.org/10.3389/fgene.2025.1591551 (vessoni2020cockaynesyndromethe pages 1-2, spitz2021diagnosticandseverity pages 1-2, chen2025clinicalandgenetic pages 1-2)
Prognosis and survival Severity groups: type I/classical median life expectancy ~16 y; type II/severe ~5 y; type III/mild >30 y. In CoSyNH (n=102), 28/102 died, mean age at death 8.4 y (range 17 months–30 y). Strongest prognostic marker: cataracts before age 3; ~60% 5-year survival with early cataracts vs 95% without. Pneumonia/respiratory disease is the most common cause of death. Natural-history cohort; review Wilson et al. (2016-05) https://doi.org/10.1038/gim.2015.110; Vessoni et al. (2020-05) https://doi.org/10.1590/1678-4685-gmb-2019-0085 (wilson2016thecockaynesyndrome pages 2-3, wilson2016thecockaynesyndrome pages 9-10, vessoni2020cockaynesyndromethe pages 1-2)
Core phenotypes with frequencies CoSyNH frequencies: muscle weakness 80/102 (~78%); hearing loss 64/102 (~63%); tremor 66/102 (~65%); joint contractures 64/102 (~63%); gastroesophageal reflux 54/102 (~53%); scoliosis 49/102 (~48%); cataracts 47/102 (~46%); seizures 23/102 (~23%); respiratory disease 20/102 (~20%). Additional reported frequencies: subcutaneous fat loss 56%; intracranial calcification 55% (47/85 imaged); white matter changes 38% (33/85); hypertension 18% (12/67); abnormal glucose 13% (6/47). Natural-history cohort Wilson et al. (2016-05) https://doi.org/10.1038/gim.2015.110 (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 6-8, wilson2016thecockaynesyndrome pages 2-3)
Neuroimaging hallmarks Hallmark triad: hypomyelination, intracerebral calcifications, progressive brain atrophy. Calcifications often in putamen (15/18 in one cohort), also cortex/sulcal depths and dentate nuclei. Progressive atrophy involves supratentorial white matter, cerebellum, corpus callosum, brainstem. MRS: elevated lactate, reduced NAA and Cho. Findings aid differential diagnosis vs congenital CMV, Aicardi-Goutières, Pelizaeus-Merzbacher disease, and mitochondrial disorders. Human imaging cohort; pathology review Koob et al., AJNR (2010-10), DOI: 10.3174/ajnr.a2135, https://doi.org/10.3174/ajnr.a2135; Rapin et al., J Child Neurol (2006-11), DOI: 10.1177/08830738060210110101, https://doi.org/10.1177/08830738060210110101 (koob2010neuroimagingincockayne pages 1-2, koob2010neuroimagingincockayne pages 7-8, koob2010neuroimagingincockayne pages 8-9, koob2010neuroimagingincockayne pages 2-4, rapin2006cockaynesyndromein pages 15-21, rapin2006cockaynesyndromein pages 10-11)
Diagnostic and severity scoring 10-item clinical diagnostic score: short stature, enophthalmos, hearing loss, cataracts, cutaneous photosensitivity, frequent dental caries, enamel hypoplasia, abnormal tooth morphology, areflexia, spasticity. Performance: 95.7% sensitivity, 86.4% specificity at threshold 8.5. 12-item clinical-radiological score (adds leukodystrophy and brain calcifications): 96.2% sensitivity, 96.8% specificity at threshold 15.5. Severity score uses 5 items: head circumference, weight/height, neurosensory signs, autonomy/motor development, communication. Human molecularly confirmed cohort (n=69 for score development) Spitz et al. (2021-02) https://doi.org/10.1186/s13023-021-01686-8 (spitz2021diagnosticandseverity pages 1-2, spitz2021diagnosticandseverity pages 4-5, spitz2021diagnosticandseverity pages 2-4)
2024 development: adult late-stage neurologic complications Adult cohort surviving >18 y (n=18): neurocognitive/neuropsychiatric decline in 17/18 (94.4%); tremor 15/18 (83.3%); neuropathy 13/18 (72.2%); progressive language decline 15/17 (88.2%); seizures 5/18 (27.8%); stroke/TIA 4/18 (22.2%); loss of ambulation 8/18 (44.4%). Imaging among those with data: diffuse atrophy 13/15 (86.7%), white-matter changes 12/15 (80.0%), basal ganglia calcifications 11/15 (73.3%). Human retrospective multicenter adult cohort Rajamani et al., Neurol Clin Pract (2024-08), DOI: 10.1212/cpj.0000000000200309, https://doi.org/10.1212/cpj.0000000000200309 (rajamani2024cognitivedeclineand pages 5-9, rajamani2024cognitivedeclineand pages 9-13)
2024 development: iPSC brain organoids / neurospheres CSB-deficient patient iPSC-derived neurospheres and cerebral organoids showed early dysregulation of VEGFA-VEGFR2 signaling, vesicle-mediated transport, and head development at NPC/neurosphere stage; organoids showed downregulation of brain development, neuron projection development, and synaptic signalling. Shared metabolic signature: upregulated steroid/cholesterol biosynthesis. Supports CS as both neurodevelopmental and neurodegenerative. Human patient-derived iPSC/organoid transcriptomics (preprint) Szepanowski et al., bioRxiv (2024-10), DOI: 10.1101/2023.10.17.562706, https://doi.org/10.1101/2023.10.17.562706 (szepanowski2024cockaynesyndromepatient pages 1-3, szepanowski2024cockaynesyndromepatient pages 13-17, szepanowski2024cockaynesyndromepatient pages 19-21, szepanowski2024cockaynesyndromepatient pages 10-13)
2024 development: nicotinamide supplementation In CS patient fibroblasts, oxidative-stress profiling identified activation of arachidonic acid metabolism and repression of NRF2 pathway. Nicotinamide (NAM) was reported to enhance autophagy, reduce inflammatory signals, increase PRDX3/FOXM1, decrease ALOX12/TNF-α/NF-κB-related markers, and restore POLG1 depletion in fibroblasts. Evidence is exploratory and limited by small sample numbers and cell-model design. Patient-derived fibroblast in vitro study Chikhaoui et al., Aging (Albany NY) (2024-11), DOI: 10.18632/aging.206160, https://doi.org/10.18632/aging.206160 (chikhaoui2024supplementationwithnicotinamide pages 1-2, chikhaoui2024supplementationwithnicotinamide pages 9-11, chikhaoui2024supplementationwithnicotinamide pages 2-5, chikhaoui2024supplementationwithnicotinamide pages 8-9)
Trial: Prodarsan NCT01142154; Phase I/II, open-label, single-group PK/safety study of oral Prodarsan (D-mannitol formulation) in pediatric CS; n=5, completed. Oral dosing TID for 6–8 days with escalation to target dose; compared PK after oral Prodarsan vs IV Osmitrol (mannitol). Primary endpoint: D-mannitol PK; key secondary endpoint: short-term safety/tolerability. Interventional clinical trial registry ClinicalTrials.gov, NCT01142154, “Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome” (start 2010-06; primary completion 2010-09; completion 2011-02), https://clinicaltrials.gov/study/NCT01142154 (NCT01142154 chunk 1)
Trial: METABO-CS NCT03044210; interventional metabolic/basic-science study, University Hospital Strasbourg; planned n=25, status TERMINATED (“pas assez de patients”). Primary endpoint: resting energy expenditure by indirect calorimetry vs Black equation; secondary endpoints included hormonal axes, lactate/pyruvate, respiratory quotient, body composition; included CS patients and sibling controls. Interventional clinical trial registry ClinicalTrials.gov, NCT03044210, “Metabolic Study of Cockayne Syndrome” (start 2017-04-04; completion listed 2024-08-01), https://clinicaltrials.gov/study/NCT03044210 (NCT03044210 chunk 1)
Trial/registry: NIH DNA repair disorders protocol NCT00001813; prospective NIH/NCI observational case-control protocol across DNA repair disorders including CS; 709 participants, status COMPLETED. Objectives relevant to CS: detailed clinical phenotyping, longitudinal follow-up, skin/blood/hair/buccal sampling, DNA-repair and molecular analyses, genotype-phenotype correlation, documentation of cancers/atypical features, counseling/education. Observational clinical protocol registry ClinicalTrials.gov, NCT00001813, “Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair...” (start 1999-05-10; completed; updated 2026-04-22), https://clinicaltrials.gov/study/NCT00001813 (NCT00001813 chunk 1)
Trial/registry: DNage natural history NCT00985413 (alias NCT01230333); observational pediatric natural-history study; estimated n=40; status TERMINATED because DNage entered receivership. Focused on natural progression with emphasis on growth and hearing; primary analytic objective was rate of linear growth over 6 or 12 months depending on age; biospecimens included blood, urine, tissue. Observational natural-history registry ClinicalTrials.gov, NCT00985413, “Observational Study to Assess Natural History in Cockayne Syndrome Patients” (2009), https://clinicaltrials.gov/study/NCT00985413 (NCT00985413 chunk 1)

Table: This table condenses the most actionable disease-level evidence for Cockayne syndrome, including genetics, phenotype frequencies, prognosis, diagnostics, recent 2024 mechanistic advances, and key trial records. It is designed for direct use in a structured knowledge base entry.

Notes on evidence gaps (important for knowledge-base curation)

  1. Core CS ontology identifiers (OMIM/ORPHA/MeSH/ICD/MONDO) were not present in the retrieved excerpts; only XP-CS identifiers were explicitly captured. (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)
  2. PMIDs were not present in the retrieved text excerpts, so this report cannot provide PMID-tagged citations from within the current evidence corpus.
  3. Carrier frequency, founder variant prevalence, and validated protective factors were not retrievable from the current evidence corpus.

References

  1. (wilson2016thecockaynesyndrome pages 1-2): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.

  2. (vessoni2020cockaynesyndromethe pages 1-2): Alexandre Teixeira Vessoni, Camila Chaves Coelho Guerra, Gustavo Satoru Kajitani, Livia Luz Souza Nascimento, and Camila Carrião Machado Garcia. Cockayne syndrome: the many challenges and approaches to understand a multifaceted disease. Genetics and Molecular Biology, May 2020. URL: https://doi.org/10.1590/1678-4685-gmb-2019-0085, doi:10.1590/1678-4685-gmb-2019-0085. This article has 64 citations and is from a peer-reviewed journal.

  3. (chikhaoui2024supplementationwithnicotinamide pages 1-2): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.

  4. (szepanowski2024cockaynesyndromepatient pages 1-3): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.

  5. (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2): Valerie A. I. Natale and Hayley M Raquer. Xeroderma pigmentosum-cockayne syndrome complex. Orphanet Journal of Rare Diseases, Apr 2017. URL: https://doi.org/10.1186/s13023-017-0616-2, doi:10.1186/s13023-017-0616-2. This article has 112 citations and is from a peer-reviewed journal.

  6. (spitz2021diagnosticandseverity pages 2-4): M. A. Spitz, F. Severac, C. Obringer, S. Baer, N. Le May, N. Calmels, and V. Laugel. Diagnostic and severity scores for cockayne syndrome. Orphanet Journal of Rare Diseases, 16:1-10, Feb 2021. URL: https://doi.org/10.1186/s13023-021-01686-8, doi:10.1186/s13023-021-01686-8. This article has 32 citations and is from a peer-reviewed journal.

  7. (wilson2016thecockaynesyndrome pages 2-3): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.

  8. (spitz2021diagnosticandseverity pages 1-2): M. A. Spitz, F. Severac, C. Obringer, S. Baer, N. Le May, N. Calmels, and V. Laugel. Diagnostic and severity scores for cockayne syndrome. Orphanet Journal of Rare Diseases, 16:1-10, Feb 2021. URL: https://doi.org/10.1186/s13023-021-01686-8, doi:10.1186/s13023-021-01686-8. This article has 32 citations and is from a peer-reviewed journal.

  9. (koob2010neuroimagingincockayne pages 1-2): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.

  10. (NCT01142154 chunk 1): Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome. DNage B.V.. 2010. ClinicalTrials.gov Identifier: NCT01142154

  11. (NCT03044210 chunk 1): Metabolic Study of Cockayne Syndrome. University Hospital, Strasbourg, France. 2017. ClinicalTrials.gov Identifier: NCT03044210

  12. (NCT00001813 chunk 1): Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy. National Cancer Institute (NCI). 1999. ClinicalTrials.gov Identifier: NCT00001813

  13. (wilson2016thecockaynesyndrome pages 3-4): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.

  14. (wilson2016thecockaynesyndrome pages 6-8): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.

  15. (rajamani2024cognitivedeclineand pages 5-9): Geetanjali Rajamani, Seth A. Stafki, Audrey L. Daugherty, William G. Mantyh, Hannah R. Littel, Christine C. Bruels, Christina A. Pacak, Paul D. Robbins, Laura J. Niedernhofer, Adesoji Abiona, Paola Giunti, Shehla Mohammed, Vincent Laugel, and Peter B. Kang. Cognitive decline and other late-stage neurologic complications in cockayne syndrome. Neurology Clinical Practice, Aug 2024. URL: https://doi.org/10.1212/cpj.0000000000200309, doi:10.1212/cpj.0000000000200309. This article has 5 citations.

  16. (wilson2016thecockaynesyndrome pages 9-10): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.

  17. (chen2025clinicalandgenetic pages 1-2): Jing Chen, Wei Su, Dan Gao, Fangfang Liu, Shuang Chen, Wenhan Zhang, Min Peng, Tao Lei, and Hongmin Zhu. Clinical and genetic analysis of ercc8-related cockayne syndrome: hepatic dysfunction as a biomarker, anhidrosis as a rare feature, and rehabilitation outcomes for ankle contractures. Frontiers in Genetics, Aug 2025. URL: https://doi.org/10.3389/fgene.2025.1591551, doi:10.3389/fgene.2025.1591551. This article has 1 citations and is from a peer-reviewed journal.

  18. (szepanowski2024cockaynesyndromepatient pages 19-21): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.

  19. (chikhaoui2024supplementationwithnicotinamide pages 9-11): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.

  20. (rapin2006cockaynesyndromein pages 10-11): Isabelle Rapin, Karen Weidenheim, Yelena Lindenbaum, Pearl Rosenbaum, Saumil N. Merchant, Sindu Krishna, and Dennis W. Dickson. Cockayne syndrome in adults: review with clinical and pathologic study of a new case. Journal of Child Neurology, 21:1006-991, Nov 2006. URL: https://doi.org/10.1177/08830738060210110101, doi:10.1177/08830738060210110101. This article has 167 citations and is from a peer-reviewed journal.

  21. (koob2010neuroimagingincockayne pages 7-8): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.

  22. (wilson2016thecockaynesyndrome pages 8-9): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.

  23. (spitz2021diagnosticandseverity pages 4-5): M. A. Spitz, F. Severac, C. Obringer, S. Baer, N. Le May, N. Calmels, and V. Laugel. Diagnostic and severity scores for cockayne syndrome. Orphanet Journal of Rare Diseases, 16:1-10, Feb 2021. URL: https://doi.org/10.1186/s13023-021-01686-8, doi:10.1186/s13023-021-01686-8. This article has 32 citations and is from a peer-reviewed journal.

  24. (koob2010neuroimagingincockayne pages 8-9): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.

  25. (NCT00985413 chunk 1): Observational Study to Assess Natural History in Cockayne Syndrome Patients. DNage B.V.. 2009. ClinicalTrials.gov Identifier: NCT00985413

  26. (nascimento2022neurodegeneraçãonoenvelhecimento pages 46-66): Lívia Luz Souza Nascimento. Neurodegeneração no envelhecimento: lições da síndrome de cockayne. ArXiv, 2022. URL: https://doi.org/10.11606/t.42.2022.tde-15082022-114300, doi:10.11606/t.42.2022.tde-15082022-114300. This article has 0 citations.

  27. (koob2010neuroimagingincockayne pages 2-4): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.

  28. (rapin2006cockaynesyndromein pages 15-21): Isabelle Rapin, Karen Weidenheim, Yelena Lindenbaum, Pearl Rosenbaum, Saumil N. Merchant, Sindu Krishna, and Dennis W. Dickson. Cockayne syndrome in adults: review with clinical and pathologic study of a new case. Journal of Child Neurology, 21:1006-991, Nov 2006. URL: https://doi.org/10.1177/08830738060210110101, doi:10.1177/08830738060210110101. This article has 167 citations and is from a peer-reviewed journal.

  29. (rajamani2024cognitivedeclineand pages 9-13): Geetanjali Rajamani, Seth A. Stafki, Audrey L. Daugherty, William G. Mantyh, Hannah R. Littel, Christine C. Bruels, Christina A. Pacak, Paul D. Robbins, Laura J. Niedernhofer, Adesoji Abiona, Paola Giunti, Shehla Mohammed, Vincent Laugel, and Peter B. Kang. Cognitive decline and other late-stage neurologic complications in cockayne syndrome. Neurology Clinical Practice, Aug 2024. URL: https://doi.org/10.1212/cpj.0000000000200309, doi:10.1212/cpj.0000000000200309. This article has 5 citations.

  30. (szepanowski2024cockaynesyndromepatient pages 13-17): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.

  31. (szepanowski2024cockaynesyndromepatient pages 10-13): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.

  32. (chikhaoui2024supplementationwithnicotinamide pages 2-5): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.

  33. (chikhaoui2024supplementationwithnicotinamide pages 8-9): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.